Objective: The prognosis for gastric carcinoma patients with liver metastasis is very poor. This retrospective study investigated the prognostic significance of MK-1 expression in gastric carcinoma patients with liver metastasis. Methods: Immunohistochemical staining using monoclonal antibody FU-MK-1 against MK-1 antigen was performed on paraffin-embedded tissues from 64 gastric carcinoma patients with liver metastasis. We attempted to determine the presence of any relationship between pathological prognostic factors and the expression of MK-1 in 64 gastric carcinoma patients with liver metastasis. Results: MK-1 expression was found in 43 (67%) of 64 tumor samples. MK-1 expression was significantly higher in the intestinal type (73%) than in the diffuse type carcinoma (33%, P ¼ 0.049). Multivariate analysis showed that MK-1 expression and lymph node metastasis were significant factors for overall survival. The difference between overall survival rates with positive or negative MK-1 expression was statistically significant as shown by Kaplan -Meier survival analysis (P , 0.0001; log-rank). In addition, the difference between cumulative disease-free survival rates with positive or negative MK-1 expression in gastric carcinoma patients with metachronous liver metastasis was statistically significant as well, as shown by Kaplan -Meier survival analysis (P ¼ 0.0006; log-rank). Conclusions: The prognostic significance of MK-1 expression as a biological tumor marker was demonstrated in a series of gastric carcinoma patients with liver metastasis. MK-1 positivity may be a reliable marker for predicting and taking measures to control liver metastasis after curative gastrectomy for gastric carcinoma.
INTRODUCTION
Gastric carcinoma (GC) is one of the major causes of cancer-related death in the world, even though its incidence has decreased over the years (1) . GC is the second most common cause of death due to cancer in Japan (2) . Radical surgical treatment including lymph node dissection and adjuvant chemotherapy is used for patients with primary GC (3) . But many patients suffer from a variety of metastatic patterns. Among these, liver metastasis (LM) of gastric cancer after curative gastrectomy is one of the most important factors for prognosis. This is found in 3 -5% of patients with GC (4, 5) , predicting a 5-year survival of ,10% (6), as current treatments are uncertain and ineffective. Considering the potential of adjuvant chemotherapy to improve the prognosis of GC with LM, it is imperative to identify any appropriate prognostic markers.
The monoclonal antibody (MAb) FU-MK-1, which recognizes the MK-1 antigen, was established by immunizing a mouse with cancerous ascites derived from a poorly differentiated adenocarcinoma of the stomach (7) . The target molecule of FU-MK-1 is encoded by the GA733-2 gene and the epitope for MAb FU-MK-1 is present on the distal half of the extracellular domain of the GA733-2 antigen. More than 20 antibodies directed against the GA733-2 antigen have been generated, including HEA125 for Ep-CAM, CO17-1A for 17-1A and FU-MK-1 for MK-1. However, because of the differences in their immunohistochemical reactivities, FU-MK-1 might recognize a different epitope group than that recognized by Ep-CAM and 17-1A (8) . Some reports suggested that the epithelial cellular adhesion molecule is an attractive immunotherapeutic target to overcome the metastasis of a variety of epithelium-oriented cancers (9 -11) .
In this study, we attempted to determine the presence of any relationship between pathological prognostic factors and the expression of MK-1 in GC patients with LM.
PATIENTS AND METHODS

PATIENTS
A total of 64 GC patients with LM after gastrectomy from 1994 to 2007 were included: 26 patients with synchronous LM and 38 patients with metachronous LM; whereas those with recurrent lesions in other locations as well were excluded. All patients underwent preoperative diagnosis, resection and postoperative follow-up in the Department of Surgery at Fukuoka University. Patients comprised 49 men and 15 women, ranging in age from 38 to 88 years (mean + SD, 65.3 + 9.9 years). Follow-up ranged from 1 to 147 months and the median was 27 months. CT scans were obtained with every visit.
TUMOR SAMPLES AND HISTOLOGIC EXAMINATION
Tissue samples were fixed in 10% formalin and cut into 3-to 4-mm slices. The tissue blocks were taken from the tumor and then routinely processed to paraffin sections (3 mm). All sections were stained with hematoxylin and eosin (H&E) and examined. The pathologic diagnosis and classification of the primary cancer were performed by a minimum of two pathologists according to the Japanese Classification of Gastric Carcinoma (12) . Tumors were histologically classified into two types based on the predominant features according to the criteria of Lauren (13) ; well differentiated, moderately differentiated and papillary adenocarcinomas were categorized as intestinal type carcinomas; and poorly differentiated adenocarcinomas and signet ring cell carcinomas as diffuse type carcinomas. In all cases, additional staining using Victoria blue-H&E double stains (VB-HE) was performed for the evaluation of venous permeation by the carcinoma.
IMMUNOHISTOCHEMICAL ANALYSIS
Sixty-four tumor specimens were obtained at surgery. All specimens were formalin-fixed, paraffin-embedded and immunohistochemically stained with MAb FU-MK-1 as described previously (7) . Stained slides were evaluated in all cases. An FU-MK-1 reaction was defined as the presence of specific staining on the surface membranes of tumor cells. The reaction was evaluated for membranous and occasional cytoplasmic staining. MK-1 expression was determined to be positive when more than 10% of tumor cells exhibited a positive reaction for the FU-MK-1 antibody. In all cases, additional immunostaining using MAb D2-40 was performed for the evaluation of lymphatic permeation by the carcinoma.
STATISTICAL ANALYSIS
The relationship between MK-1 expression and clinicopathologic factors was analyzed by using the x 2 test, Fisher's exact probability test and Spearman's rank correlation test using StatView, version 5.0 (SAS Institute, Cary, NC). Survival curves were obtained by using the Kaplan -Meier method and compared by using the log-rank test. Multivariate analysis of prognostic factors was based on the Cox proportional hazards model. Results were considered significant if a two-sided P value of ,0.05 was obtained.
RESULTS
The FU-MK-1 antibody did not react with the gastric foveolar epithelium, but it reacted strongly with the membranes of the gastric mucosa with intestinal epithelial metaplasia ( Fig. 1A and B) . MK-1 expression was found in 43 (67%) of 64 GC patients with LM samples. The expression was strongly and diffusely located in the cell membranes of carcinoma ( Fig. 2A and B) . No MK-1 expression was found in 21 (33%) of 64 GC with LM samples (Fig. 3A and B) . These are the MK-1 expression of tumor cells with lymphatic or venous permeation by the carcinoma (Fig. 4A and B) . D2-40 and VB-HE were performed for the evaluation of lymphatic or venous permeation by the carcinoma. The relationship between MK-1 expression and clinicopathologic variables is shown in Tables 1 and 2 . In relation to tumor histologic type, MK-1 expression was significantly but marginally higher (P ¼ 0.049) in the intestinal type (40 patients; 73%) than in diffuse type carcinomas (3 patients; 33%). The presence of lymph node metastasis or venous permeation was also correlated with MK-1 expression. However, MK-1 expression did not reach statistical significance for other clinicopathologic variables.
The mean survival time of the 64 patients was 26 + 3 months (mean + SEM), and no perioperative mortality occurred. The median survival time of the MK-1 positive group was 19 months, while that of the negative group was 38 months. The difference between the overall survival rates with positive or negative MK-1 expression was statistically significant as shown by the Kaplan -Meier survival analysis (P , 0.0001; log-rank) (Fig. 5) .
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MK-1 in gastric carcinoma with liver metastasis In addition, with respect to disease-free survival before metachronous LM, the median disease-free survival time of the MK-1 positive group was 9 months, while that of the negative group was 19 months. The difference between cumulative disease-free survival rates with positive or negative MK-1 expression was also statistically significant as shown by the Kaplan -Meier survival analysis (P ¼ 0.0006; log-rank) (Fig. 6) .
Univariate analysis showed that MK-1 expression and lymph node metastasis were significant factors for overall survival. Multivariate analysis also revealed that MK-1 expression and lymph node metastasis were prognostic factors for overall survival (Table 3) .
DISCUSSION
While many studies have reported the benefit of hepatectomy for metastatic tumors from colorectal cancer (14 -16) , in the case of liver metastases from GC only a few reports have dealt with the results of hepatectomy.
Hepatectomy is a popularly curative therapy for patients with LM from colorectal carcinoma, presenting a 5-year survival rate of 30 -50%. However, hepatectomy for GC metastasis has worse results with a 1-year survival rate of 15 -50% and 5-year survival rate of 19% (17 -21) . Because GC metastases are often multiple, scattered and bilobular, recurring with a combination of various patterns, current treatments such as systemic or hepatic artery infusion chemotherapy and surgical therapy are uncertain and ineffective.
Yamashita et al. (22) reported that the microvessel density was significantly higher in the intestinal-type GC than in diffuse-type carcinoma and was strongly associated with a poor outcome in the intestinal-type carcinoma with hepatic metastases. Takahashi et al. (23) reported that VEGF and VEGFR expressions were higher in the intestinal-type than in diffuse-type GC, and that intestinal type tends to be exophytic, metastasizing to the liver by hematogenous dissemination. In our study, the intestinal-type GC (55 patients; 86%) was more frequent than diffuse type (9 patients; 14%).
Watanabe et al. (7) reported that MK-1 expression may be useful for classifying cancers of the stomach and for 380 MK-1 in gastric carcinoma with liver metastasis detecting the metastatic foci of gastrointestinal adenocarcinoma in the lymph nodes and other organs. Hamada et al. (24) reported that MK-1 expression in carcinoma of the ampulla of Vater was significantly associated with histologic grades and was an independent prognostic factor of increased overall survival. Ikeda et al. (25) also reported similar results in gallbladder carcinoma. In our study, MK-1 expression was significantly higher in the intestinal-type than in diffuse-type GC (73 versus 33%). Multivariate analysis revealed that MK-1 expression and lymph node metastasis were prognostic factors for overall survival. We also show a significant relationship with poor overall survival and disease-free survival by Kaplan -Meier curves. Positive MK-1 expression was associated with a poor prognosis. We considered two reasons for this with biological background. First, Ep-CAM becomes part of a large nuclear complex containing transcriptional regulators b-catenin and Lef, which are both components of the wnt pathway (26) . And it was associated with tumor cell proliferation, migration and invasion. Secondly, Ep-CAM was shown to interact directly with CD44v4-v7 and they supported tumor progression by promoting metastasis (27) . The relationship between lymph node metastasis and prognosis is well known (28) . The high frequency of intestinaltype GC in our series of GC with LM may be consistent with the particular cell adhesion qualities of this histology, allowing easier penetration of the vascular wall at either the primary or metastatic tumor site and facilitating spread in the liver.
Ep-CAM is regarded as an antigen similar to MK-1 and there are some reports about Ep-CAM expression in GC. Songun et al. (29) reported that patients without the loss of Ep-CAM-expression by tumor cells had a significantly better 10-year survival rates compared with patients with any loss of expression. Went et al. (30) reported that on the GC microarray, 90.7% of the tumors expressed Ep-CAM on .70% of cells and 85.8% of the cases showed the highest level of staining intensity. No significant correlation of Ep-CAM expression between primary tumors, nodal spread or metastasis was found. Wengi et al. (31) reported that the average expression of Ep-CAM was higher in poorly differentiated tumor cells than in well and moderately differentiated tumor cells, and that Ep-CAM expression in patients with lymph node metastasis was significantly higher than that in patients without metastasis. In various reports about Ep-CAM expression by GC, results are inconsistent. In our study, the expression of Ep-CAM was positive in all patients with LM after curative gastrectomy. There is a discrepancy between previous studies using Ep-CAM and our results using MK-1. Because it is not clear why MK-1 expression differs in various organs or sites and different cancers, systematic analysis using a wide variety of normal human tissue and neoplasms is necessary.
In conclusion, the prognostic significance of MK-1 expression as a biological tumor marker was demonstrated in a series of GC patients with LM, predicting decreased median survival time and decreased median disease-free survival time. The prognostic significance of lymph node metastasis was similar. MK-1 positivity may be useful as a reliable marker for predicting and taking steps to control LM after curative gastrectomy for GC as an immunotherapeutic target. 
